Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants
NCT: NCT06373289 · RECRUITING
Brief Summary
Around 50% of infants born extremely preterm develop a chronic lung disease known as bronchopulmonary dysplasia of which some infants will also develop pulmonary hypertension of which 50% of children will die before the age of 2. Physicians are currently limited in their ability to select the most appropriate oxygen targets that will improve outcomes in infants with this condition. This clinical trial will determine whether using different amounts of oxygen improve outcomes in infants with this disease.
Frequently Asked Questions
What is Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants?
Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants is a clinical trial registered under NCT06373289. Current status: RECRUITING.
What is the status of NCT06373289?
The current status of NCT06373289 (Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants) is: RECRUITING.
When did Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants start?
Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants started on 2026-04.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.